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Synthesis of some benzimidazole derivatives endowed with 
1,2,3-triazole as potential inhibitors of hepatitis C virus
New derivatives of 2-thiobenzimidazole incorporating tri-
azole moiety were synthesized, characterized and tested in 
vitro for antiviral activity against hepatitis C virus (HCV) 
and hepatitis B virus (HBV). Their cytotoxicity was de ter-
mi ned by the reduction in the number of viable cell. All of 
the synthesized compounds are inactive against HBV and 
some showed activity against HCV. In particular, two com-
pounds showed significant activity, 2-{4-[(1-benzoylbenz-
imidazol-2-ylthio)methyl]-1H-1,2,3-triazol-1-yl}-N-(p-nitro -
-phenyl)- acetamide (13) and 2-(4-{[1-(p-chloro benzoyl)- benz-
imidazol-2-ylthio)methyl]-1H-1,2,3-triazol-1-yl}-N-(p-ni tro-
phenyl)-acetamide (17). The results give an insight into the 
importance of the substituent at position 2 of benzimid-
azole for the inhibition of HCV.
Keywords: benzimidazole, triazole, anilide, antiviral, HCV, 
HBV
 
Hepatitis C virus (HCV), a member of the Hepacvirus genus of the family Flavivridae, 
is a major etiological agent of human liver disease. HCV has infected an estimated 170 
million people worldwide. HCV infection is often asymptomatic; however, it frequently 
causes chronic hepatitis, which progresses to the end-stage liver diseases, such as liver 
cirrhosis and hepatocellular carcinoma. For a long time, the therapeutic combination of 
pegylated alpha interferon (peg-IFN) and the nucleoside analogue ribavirin were used for 
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HCV treatment and were found to have a sustained viral response (SVR) rate of ~50 % in 
genotype 1 and 4 of HCV-infected patients (1). Recently, a new anti-HCV agent (Sofosbu-
virR) was added to the above mentioned combination and produced improvement in the 
SVR up to ~90 % (1). However, peg-IFN and ribavirin should be included for successful 
treatment, particularly in the treatment of genotype 4. Combined therapy of HCV infec-
tions with peg-IFN is associated with serious side effects such as depression, flu-like symp-
toms, fatigue and hemolytic anemia caused by ribavirin (2, 3).
Therefore, finding a single compound for the treatment of HCV that promises to cure 
the majority of patients without the complications of combined therapy and/or the need 
for painful injections would be a good achievement.
Owing to its isosterism with indole and purine nuclei present in many fundamental 
cellular components and bioactive compounds, the benzimidazole ring represents a kind 
of privileged substructure from which several important drugs used in different therapeu-
tic areas have been obtained, especially antitumor and antiviral agents. Among the anti-
viral benzimidazoles, an important position is held by compounds acting against HIV-1, 
HCV and respiratory syncytial virus (RSV) (4, 5).
The benzimidazole scaffold is common in different anti-HCV agents with different 
modes of action. Derivatives of bis-benzimidazolemethane were discovered to be highly 
potent, reversible and selective serine protease inhibitors (6, 7). Furthermore, by replacing 
the 2-methylbenzimidazole moiety of this compound with 2-pyrimidomethylenethio moi-
ety or its bioisosteric 2-pyrimidomethyleneamino group was shown to have a positive 
impact on the inhibitory activity against HCV (8). Moreover, several 2-substituted benz-
imidazoles showed good antiviral activity (9, 10).
The antiviral activity was found in all the subsets of benzimidazole derivatives, but it 
was not evenly distributed among them. The activity is a result of several interacting struc-
tural features, which may direct it vs. specific viruses, modulating also their potency (11).
On the other hand, the 1,2,3-triazole core has been applied in many synthetic ap-
proaches. Several compounds containing this heterocycle exhibited a broad range of bio-
logical activities including against HIV and HCV (12–15).
Considering the importance of 2-substituted benzimidazole and triazole nucleus, it 
was thought worthwhile to design and synthesize some new 2-substituted benzimidazole 
derivatives connected to differently substituted anilides with triazole moiety (Fig. 1) and 
to screen them for their potential antiviral activity. This approach may provide scaffolds 




Reagents and solvents. – All reagents and solvents were obtained from commercial sup-
pliers and were used without further purification. The starting materials, 2-(prop-2-ynyl- 
thio)-1H-benzimidazole (1, 16), 2-azido-N-phenylacetamide (3a), 2-azido-N-(p-chlorophe-
nyl)acetamide (3b), 2-azido-N-(p-bromophenyl)acetamide (3c), 2-azido-N-(p-methylphenyl)
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acetamide (3d) and 2-azido-N-(p-nitrophenyl)acetamide (3e) were prepared according to 
reported procedures (17).
Procedures. – Melting points are uncorrected and were determined on an electrothermal 
melting point apparatus (Stuart Scientific, model SMP3, UK). Precoated silica gel plates (Kie-
selgel 0.25 mm, 60G F254, Merck, Germany) were used for TLC monitoring of the reactions. 
The developing solvent system CH2Cl2/CH3OH (9.5:0.5, V/V) was used and the spots were 
detected at 254 nm using an ultraviolet lamp (model CM-10, Spectroline, USA).
IR spectra (KBr discs) were recorded on a Shimadzu IR-470 spectrometer (Shimadzu, 
Japan). 1H (500 MHz) and 13C NMR (125 MHz) spectra were obtained with JEOL JNM-ECA 
500 spectrometer (JEOL, Japan) with tetramethylsilane (TMS) as an internal standard. 
Chemical shifts were expressed in δ-value (ppm) relative to TMS. DMSO-d6 was used as a 
solvent. Addition of deuterium oxide was used for the detection of exchangeable protons. 
Mass spectra were recorded with a JEOL JMS600 mass spectrometer.
2-Acyl-1-propargyl-thiobenzimidazoles (2a–c). General procedure. – To a suspension of 
2-(prop-2-ynyl-thio)-1H-benzimidazole (1) (188 mg, 1 mmol) (16) and potassium carbonate 
anhydrous (145 mg, 1.05 mmol, 1.05 equivalent) in dry acetone (10 mL), the appropriate acyl 
halide (1.05 equivalent) was added. The reaction mixture was stirred for 12–18 h at ambient 
temperature. Acetone was evaporated, the residue was treated with water and then ex-
tracted with CH2Cl2 (3 x 10 mL). The organic extract was washed with water, dried over 
anhydrous Na2SO4 and then concentrated. The obtained crude products were recrystal-
lized from DMF/H2O (7:3).
2-{4-[(1-Acylbenzimidazol-2-yl-thio)methyl]-1H-1,2,3-triazol-1-yl}-N-(unsubstituted/substi-
tuted phenylacetamides (4–18). General procedure. – To a solution of propargyl derivatives 1 or 
2a–c (1.3 mmol) in a mixture of THF/H2O (12 mL, 2:1), the reported azide derivatives 3a–e 
(17) (1.6 mmol), copper sulphate (0.13 mmol) and sodium ascorbate (0.26 mmol) were added. 
The resulting mixture was stirred at room temperature for 20 h, and the residue was ex-
tracted with CH2Cl2 (3 x 15 mL). The organic phase was washed with water, dried over an-
hydrous Na2SO4 and concentrated. The crude product was purified by column chromato-
graphy using CH2Cl2/methanol (9:1) as an eluent to give pure products (4–18).
Physical and spectral data of the newly synthesized compounds (2a–c and 4–18) are 
collected in Tables I and II.
Fig. 1. Rationale for the design of target compounds 4–18.
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Table I. Physical and ESI-HRMS data of the newly synthesized compounds







2a 1-Acetyl-2-propyn-2-ylthiobenzimidazole 163–165  86  C12H11N2OS
 231.0592
231.0586
2b 1-Benzoyl-2-propyn-2-ylthiobenzimidazole 131–132 81  C17H13N2OS
 293.0749
293.0753
2c 1-p-Chlorobenzoyl-2-propyn-2-ylthiobenzimid-azole 129–130 72 C17H12ClN2OS
327.0359
327.0365
4 2-{4-[(1-Acetylbenzimidazol-2-ylthio)methyl]-1H-1,2,3-triazol-1-yl}-N-phenylacetamide 196–198 89 C20H19N6O2 S
407.1297
407.1290
5 2-{4-[(1-Acetylbenzimidazol-2-ylthio)methyl]-1H-1,2,3-triazol-1-yl}-N-(p-chlorophenyl)-acetamide 201–203 93 C20H18ClN6O2S
441.0900
441.0896
6 2-{4-[(1-Acetylbenzimidazol-2-ylthio)methyl]-1H-1,2,3-triazol-1-yl}-N-(p-bromophenyl)-acetamide 202–204 83 C20H18BrN6O2S
485.0395
485.0391
7 2-{4-[(1-Acetylbenzimidazol-2-ylthio)methyl]-1H-1,2,3-triazol-1-yl}-N-(p-methylphenyl)-acetamide 207–209 88 C21H21N6O2S
421.1447
421.1451
8 2-{4-[(1-Acetylbenzimidazol-2-ylthio)methyl]-1H-1,2,3-triazol-1-yl}-N-(p-nitrophenyl)-acetamide 195–197 87 C20H18N7O4S
452.1141
452.1141
9 2-{4-[(1-Benzoylbenzimidazol-2-ylthio)methyl]-1H-1,2,3-triazol-1-yl}-N-phenylacetamide 198–199 91 C25H21N6O2S
469.1447
469.1450
10 2-{4-[(1-Benzoylbenzimidazol-2-ylthio)methyl]-1H-1,2,3-triazol-1-yl}-N-(p-chlorophenyl)acetamide 199–201 90 C25H20ClN6O2S
503.1057
503.1060
11 2-{4-[(1-Benzoylbenzimidazol-2-ylthio)methyl]-1H-1,2,3-triazol-1-yl}-N-(p-bromophenyl)-acetamide 206–208 89 C25H20BrN6O2S
547.0552
547.0544
12 2-{4-[(1-Benzoylbenzimidazol-2-ylthio)methyl]-1H-1,2,3-triazol-1-yl}-N-(p-methylphenyl)-acetamide 197–199 89 C26H23N6O2S
483.1603
483.1604
13 2-{4-[(1-Benzoylbenzimidazol-2-ylthio)methyl]-1H-1,2,3-triazol-1-yl}-N-(p-nitrophenyl)-acetamide 201–203 91 C25H20N7O4S
514.1298
514.1292
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Antiviral activity
HepG2.2.15.7 cells and HepG2.2.15 clone, producing a high amount of HBV, Luc-neo#2 
and subgenomic HCV replicon cells with luciferase reporter used in testing anti-HBV and 
anti-HCV activity, respectively, were established and provided by Drs. Takaji Wakita and 
Koichi Watashi (Department of Virology II, National Institute of Infectious Diseases, To-
kyo, Japan). All compounds, 4–18, were screened for their anti-HBV and anti-HCV activity 
using the reported method (18, 19). Reference inhibitors were used: lamivudine (3TC) for 
HBV and telaprevir (TLV) for HCV (1). Cytotoxicity was evaluated by the reduction in the 
number of viable cells using the tetrazolium dye method (18, 19). Tetracolor One® (Sei-
kagaku Corporation, Japan) is a water-soluble tetrazolium dye that is used to determine 
the cell viability.
Each compound was dissolved in DMSO to produce 20 mmol L–1 stock solution. Each 
point in the dose-response curve represents the average of 3 readings.
Anti-HBV activity. – Determination of anti-HBV activity of benzimidazole derivatives 
was based on the inhibition of virus-induced cytopathicity. HepG2.2.15.7 cells (1 x 104 cells 
per well) were inoculated into a microtiter plate. After incubation for 24 h, the cells were 
cultured in the presence of various concentrations of the tested compounds. After incuba-
tion for 3 and 6 days, the culture medium was replaced with fresh one containing an ap-
propriate concentration of the compound. The cells were further incubated for 3 days. At 
the end of incubation, the culture supernatants were collected and examined for their HBV 
DNA levels by real-time PCR. The cells were examined for their viability by the tetrazo-
lium dye method (18, 19).
Anti-HCV activity. – The LucNeo#2 cells (5 x 103 cells per well) were cultured in a 96-
well plate in the absence of G418, an aminoglycoside commonly used to generate stable 
replicons for RNA viruses, such as hepatitis C virus, West Nile virus, and bovine viral 
diarrhoea virus (BVDV), and in the presence of various concentrations of the compounds. 
After incubation for 3 days, the culture medium was removed, and the cells were washed 
once with phosphate buffer saline (PBS). Lysis buffer was added to each well, and the ly-
sate was transferred to the corresponding well of a non-transparent 96-well plate. The lu-
ciferase activity was measured by addition of the luciferase reagent in a lucerfrease assay 
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Cytotoxicity assay. – LucNeo#2 cells (5 x 103 cells per well) were cultured in a 96-well plate 
in the absence of G418 and in the presence of various concentrations of the compounds. 
After incubation for 3 days, the culture supernatants (100 µL) were removed and the tetra-
Color ONE (10 µL) was added to each well. The cells were further incubated at 37 °C for 1 h 
the absorbance of each well was measured at 450 nm with a microplate reader (18, 19).
RESULTS AND DISCUSSION
Chemistry
In this report, hybrid molecules were prepared as illustrated in Schemes 1 and 2. Ac-
ylation of 2-(prop-2-ynyl-thio)-1H-benzimidazole (1) (16) with different acyl halides in the 
presence of anhydrous potassium carbonate in acetone afforded 1-acyl-2-propargyl-thio 
derivatives (2a–c). Structures of these compounds were established by IR, NMR and 
HRMS. In IR spectra, disappearance of the absorption band at 3410–3420 cm–1, along with 
the appearance of a strong absorption band corresponding to the carbonyl group (1680–
1700 cm–1), confirmed N-acylation. In 1H NMR spectra, 1-acetyl-2-propyn-2-yl-thiobenz-




B. G. M. Youssif et al.: Synthesis of some benzimidazole derivatives endowed with 1,2,3-triazole as potential inhibitors of hepatitis C 
virus, Acta Pharm. 66 (2016) 219–231.
 
Table II. Spectral data of the newly synthesized compounds
Compd. IR (ν, cm–1) 1H NMR (500 MHz, DMSO-d6) (δ, ppm)
13C NMR (125 MHz, 
DMSO-d6) (δ, ppm)
2a 3307 (spC-H), 3030, 
1716 (C=O), 1473, 1456, 
1371, 1315 (C=C)
7.83 (d, J = 7.9 Hz, 1H), 7.68 (d, J = 7.9 Hz, 
1H), 7.40–7.35 (m, 2 H), 4.10 (s, 2H), 3.22 
(s, 1H), 2.86 (s, 3H)
170.8, 154.2, 144.4, 133.8, 
125.3, 124.4, 119.3, 115.0, 
80.9, 74.7, 26.9, 21.0
2b
3307 (spC-H), 3010, 
1697 (C=O), 1600, 1473, 
1450, 1348, 1313 (C=C), 
1193, 700, 648
7.83–7.65 (m, 6H), 7.31 (d, J = 7.2 Hz, 1H), 
7.12 (t, J = 7.2 Hz, 1H), 6.60 (d, J = 8.2 Hz, 
1H), 4.18 (s, 2H), 3.7 (s, 1H)
168.6, 153.9, 144.2, 134.8, 
134.6, 133.6, 130.0, 129.9, 
125.3, 124.1, 119.4, 114.4, 
80.6, 75.0, 21.5
2c
3307 (spC-H), 3010, 
1697 (C=O), 1600, 1473, 
1450, 1348, 1313 (C=C), 
1193, 700, 648 
7.86 (d, J = 8.6 Hz, 2H), 7.75–7.69 (m, 
3H), 7.33–7.31 (m, 1H), 7.18–7.16 (m, 1H), 
6.71 (d, J = 8.0 Hz, 1H), 4.18 (s, 2H), 3.26 
(s, 1H)
167.6, 153.8, 144.2, 139.7, 
134.7, 132.3, 132.0, 130.2, 
125.4, 124.3, 119.4, 114.5, 
80.5, 75.1, 21.5
4
3460 (NH), 1706, 1608 
(C=O), 1576, 1544, 184, 
1475 (C=C), 715, 742
10.49 (s, 1H), 8.18 (s, 1H), 7.85 (d, J = 8.2 
Hz, 1H), 7.72 (d, J = 8.0 Hz, 1H), 7.60 (d, 
J = 8.2 Hz, 2 H), 7.39–7.35 (m, 4H), 7.12 
(t, J = 8.2 Hz, 1H), 5.34 (s, 2H), 4.62 (s, 2H), 
2.86 (s, 3H)
170.7, 165.2, 155.1, 144.5, 
143.4, 139.4, 133.9, 129.9, 
126.5, 125.2, 124.7, 124.3, 
120.2, 119.4, 115.1, 53.2, 27.5, 
27.0
5
IR3430 (NH), 1710, 1690 
(C=O), 1607, 1581, 1548, 
1456 (C=C), 840
10.63 (s, 1H), 8.18 (s, 1H), 7.85 (d, J = 8.0 
Hz, 1H), 7.70 (d, J = 6.9 Hz, 1H), 7.62 (d, J 
= 6.9 Hz, 2 H), 7.43–7.35 (4H, m), 5.35 (s, 
2H), 4.69 (s, 2H), 2.86 (s, 3H)
170.8, 165.4, 155.1, 144.6, 
143.5, 133.9, 130.2, 129.9, 
128.4, 126.5, 125.3, 124.4, 
121.8, 119.5, 115.2, 53.2, 27.6, 
27.1
6
3445 (NH), 1704, 1686 
(C=O), 1604, 1582, 1554, 
1485 (C=C), 712, 743
10.63 (s, 1H), 8.18 (s, 1H), 7.85–7.84 (m, 
3H), 7.71 (s, 1H), 7.58–7.54 (m, 2H), 
7.40–7.34 (m, 2H), 5.35 (s, 2H), 4.62 (s, 
2H), 2.86 (s, 3H)
170.5, 165.3, 154.9, 144.5, 
143.3, 138.6, 133.8, 132.6, 
126.3, 125.2, 124.2, 122.1, 
119.3, 116.3, 115.0, 53.1, 27.4, 
26.9
7
3435 (NH), 1696, 1687 
(C=O), 1608, 1554, 1492, 
1455 (C=C), 830
10.4 (s, 1H), 8.17 (s, 1H), 7.85 (d, J = 7.6 
Hz, 1H), 7.72 (d, J = 6.9 Hz, 2H), 7.47 (d, 
J = 8.2 Hz, 1H), 7.39–7.35 (m, 2H), 7.16 
(d, J = 8.2 Hz, 2H), 5.32 (s, 2H), 4.62 (s, 
2H), 2.86 (s, 3H), 2.92 (s, 3H)
170.7, 164.9, 155.1, 144.5, 
143.3, 136.8, 133.9, 133.7. 
130.2, 126.4, 125.2, 124.3, 
120.2, 119.4, 115.1, 53.3, 27.5, 
27.0, 21.4
8
3435 (NH), 1710, 1687 
(C=O), 1607, 1556, 1518, 
1456 (C=C), 837
11.10 (s, 1H), 8.27 (d, J = 9.2 Hz, 2H), 8.20 
(s, 1H), 7.86–7.84 (m, 3H), 7.71 (d, J = 7.6 
Hz, 1H), 7.40–7.35 (m, 2H), 5.43 (s, 2H), 
4.62 (s, 2H), 2.77 (s, 3H)
170.7, 166.3, 163.3, 155.0, 
145.4, 144.5, 143.5, 133.9, 
126.5, 126.1, 125.2, 124.3, 
120.0, 119.4, 115.1, 53.3, 27.5, 
27.0
9
3405 (NH), 1702, 1671 
(C=O), 1615, 1589, 1472, 
1453 (C=C), 712, 743
10.49 (s, 1H), 8.20 (s, 1H), 7.82–7.80 (m, 
1H), 7.73–7.72 (m, 2H), 7.65 (t, J = 7.9 Hz, 
1H), 7.60–7.59 (m, 3H), 7.37–7.32 (m, 3H), 
7.42 (d, J = 8.0 Hz, 1H), 7.32 (t, J = 8.0 Hz, 
1H), 7.14–7.10 (m, 2H), 5.34 (s, 2H), 4.69 
(s, 2H)
168.7, 165.1, 154.7, 144.3, 
143.2, 139.3, 134.9, 134.6, 
133.7, 130.1, 130.0, 128.4, 
126.5, 125.2, 124.7, 124.1, 
120.2, 119.4, 114.4, 53.2, 27.9
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10
3425 (NH), 1710, 1668 
(C=O), 1626, 1593, 1529, 
1474 (C=C), 837
10.64 (s, 1H), 8.19 (s, 1H), 7.82–7.80 (m, 
4H), 7.72 (d, J = 8.0 Hz, 1H), 7.66–7.62 (m, 
4H), 7.42 (d, J = 7.9 Hz, 1H), 7.42 (d, J = 8.0 
Hz, 1H), 7.32 (t, J = 8.0 Hz, 1H), 7.13 (t, J = 
8.0 Hz, 1H), 5.35 (s, 2H), 4.69 (s, 2H)
168.8, 165.4, 154.8, 144.4, 
143.3, 138.4, 135.0, 134.7, 
133.8, 130.2, 130.1, 129.9, 
128.4, 126.6, 125.3, 124.2, 
121.8, 119.5, 114.4, 53.3, 28.0
11
3435 (NH), 1710, 1669 
(C=O), 1591, 1518, 1495, 
1466 (C=C), 842
10.63 (s, 1H), 8.19 (s, 1H), 7.82–7.80 (m, 
3H), 7.72 (d, J = 8.2 Hz, 1H), 7.66–7.64 
(m, 2H), 7.58–7.54 (m, 4H), 7.33–7.11 (m, 
2H), 6.62 (d, J = 8.2 Hz, 1H), 5.35 (s, 2H), 
4.69 (s, 2H)
168.7, 165.4, 154.7, 144.3, 
143.2, 138.7, 134.9, 134.6, 
133.7, 132.7, 130.1, 130.0, 
126.5, 125.2, 124.1, 122.1, 
119.4, 116.4, 114.4, 53.2, 27.9
12
3415 (NH), 1704, 1670 
(C=O), 1593, 1551, 1561, 
1451 (C=C), 831
10.41 (s, 1H), 8.18 (s, 1H), 7.81–7.80 (m, 
2H), 7.72 (d, J = 7.9 Hz, 1H), 7.65 (t, J = 7.9 
Hz, 3H), 7.48 (d, J = 7.9 Hz, 1H), 7.32 (t, J 
= 7.6 Hz, 1H), 7.17–7.12 (m, 3H), 6.62 (d, J 
= 8.0 Hz, 1H), 5.32 (s, 2H), 4.69 (s, 2H), 
2.29 (s, 3H)
168.7, 164.9, 154.7, 144.3, 
143.1, 136.8, 134.9, 134.6, 
133.7, 133.6, 130.2, 130.1, 
130.0, 126.5, 125.2, 124.1, 
120.2, 119.4, 114.4, 53.2, 27.9, 
21.4
13
3420 (NH), 1714, 1670 
(C=O), 1616, 1593, 1561, 
1451 (C=C), 834
11.10 (s, 1H), 8.27 (d, J = 9.0 Hz, 2H), 8.21 
(s, 1H), 7.86–7.70 (m, 4H), 7.72 (d, J = 7.6 
Hz, 1H), 7.65 (t, J = 8.0 Hz, 2H), 7.32 (t, J = 
7.6 Hz, 1H), 7.12 (t, J = 7.6 Hz, 2H), 6.62 (d, 
J = 8.0 Hz, 1H), 5.44 (s, 2H), 4.70 (s, 2H)
168.7, 166.3, 154.7, 145.4, 
144.3, 143.5, 143.3, 134.9, 
134.7, 133.7, 130.1, 130.0, 
126.5, 126.0, 125.2, 124.1, 
120.0, 119.4, 114.4, 53.3, 27.9
14
3425 (NH), 1704, 1680 
(C=O), 1626, 1593, 1558, 
1475 (C=C), 830
10.49 (s, 1H), 8.19 (s, 1H), 7.85 (d, J = 8.2 
Hz, 2H), 7.73 (d, J = 8.2 Hz, 3H), 7.60 (d, 
J = 8.0 Hz, 2H), 7.38–7.32 (m, 3H), 7.12 (t, 
J = 8.2 Hz, 1H), 6.73 (d, J = 8.2 Hz, 1H), 
5.34 (s, 2H), 4.69 (s, 2H)
167.7, 165.1, 154.6, 144.3, 
143.1, 139.5, 139.3, 134.8, 
132.4, 132.2, 130.2, 129.9, 
126.5, 125.3, 124.7, 124.2, 
120.1, 119.4, 114.5, 53.2, 27.9
15
3420 (NH), 1710, 1682 
(C=O), 1622, 1592, 1552, 
1452 (C=C), 842
10.59 (s, 1H), 8.14 (s, 1H), 7.80 (d, J = 8.6 
Hz, 2H), 7.67 (d, J = 8.6 Hz, 2H), 7.57 (d, 
J = 8.5 Hz, 3H), 7.37 (t, J = 8.5 Hz, 2H), 
7.28 (t, J = 7.5 Hz, 1H), 7.12 (t, J = 7.5 Hz, 
1H), 6.67 (t, J = 8.2 Hz, 1H), 5.30 (s, 2H), 
4.64 (s, 2H)
167.8, 165.3, 154.6, 144.3, 
143.2, 139.5, 138.3, 134.8, 
132.4, 132.2, 130.2, 129.8, 
129.3, 126.5, 125.3, 124.2, 
121.7, 119.4, 114.5, 53.2, 27.9
16
3430 (NH), 1704, 1674 
(C=O), 1613, 1593, 1559, 
1486 (C=C), 837
10.59 (s, 1H), 8.16 (s, 1H), 7.82 (d, J = 8.2 
Hz, 2H), 7.70 (d, J = 8.2 Hz, 2H), 7.56–7.50 
(m, 2H), 7.58–7.54 (m, 3H), 7.30 (t, J = 8.2 
Hz, 1H), 7.14 (t, J = 8.2 Hz, 1H), 6.70 (d, J 
= 8.2 Hz, 1H), 5.32 (s, 2H), 4.66 (s, 2H)
167.2, 164.9, 154.1, 143.8, 
142.7, 139.0, 138.2, 134.3, 
132.2, 131.9, 131.7, 129.7, 
126.0, 124.8, 123.7, 121.6, 
118.9, 115.9, 114.0, 52.7, 27.5
17
3445 (NH), 1712, 1675 
(C=O), 1603, 1551, 1519, 
1453 (C=C), 837
11.10 (s, 1H), 8.27 (d, J = 9.3 Hz, 2H), 8.21 
(s, 1H), 7.86–7.84 (m, 4H), 7.74–7.72 (m, 
3H), 7.33 (t, J = 7.2 Hz, 1H), 7.17 (t, J = 7.2 
Hz, 1H), 6.72 (d, J = 8.2 Hz, 1H), 5.44 (s, 
2H), 4.70 (s, 2H)
167.7, 166.3, 154.6, 145.4, 
144.3, 143.5, 143.2, 139.5, 
134.8, 132.4, 132.1, 130.2, 
126.5, 126.1, 125.3, 124.2, 
120.0, 119.4, 114.5, 53.3, 27.9
18
3415 (NH), 1673 (C=O), 
1608, 1554, 1492, 1455 
(C=C), 830
10.36 (s, 1H), 8.10 (s, 1H), 7.52–7.43 (m, 
5H), 7.38–7.10 (m, 4 H), 5.27 (s, 2H), 4.66 
(s, 2H), 2.23 (s, 3H)
163.8, 149.7, 143.6,143.2, 
135.8, 132.7, 131.2, 129.2, 
125.3,121.7,121.2, 119.2, 
117.5, 110.4, 52.2, 25.8, 20.4
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of signals at δ 8–7 ppm confirmed the structures of 1-benzoyl-2-propyn-2-yl-thiobenzimid-
azole (2b) and 1-p-chlorobenzoyl-2-propyn-2-yl-thiobenzimidazole (2c). In 13C NMR, the 
presence of a signal in the region δ 170–168 ppm confirmed acylation. Further, reacting 
compounds 2a–c with azido compounds 3a–e (17) using the Cu alkyne-azide cycloaddi-
tion (CuAAC) (20–23) provided the target compounds 4–18 in excellent yields (85–90 %). 
In par ti cular, in each cycloadduct, the proton associated with the 1,2,3-triazole moiety was 
identified as a singlet with δ between 8.18 and 8.20 ppm. The structures of all the new 
compounds were confirmed also by mass spectral data (ESI-HRMS) where the found and 
calculated mass units are identical up to 4 decimal digits. All physical and spectral data of 
the new compounds are given in Tables I and II.
Antiviral activity
Target compounds were designed based on the available data (Fig. 1) (8–10). Benz-
imidazoles substituted at position-2 with amide, urea and/or heterocycle showed good 
anti-HCV and/or anti-HBV activity. Accordingly, and in search of a potent antiviral agent, 
2-mercaptobenzimidazoles were linked to anilides with a triazole ring. It was proposed 
that the triazole ring along with sulphur atom would improve the activity of lead molecu-
les. All synthesized compounds considered in this work were evaluated for antiviral activ-
ity against HBV and HCV.
Cytotoxicity was evaluated in parallel with the antiviral activity. The strategy follow-
ed in the antiviral screening study is based on using two concentrations (1 and 10 µmol L–1) 
of each of the test compounds. Test compounds showed no significant activity against HBV 
and weak activity toward HCV (Figs. 2a and b). Among the tested compounds, 2-{4-[(1-ben-
zoylbenzimidazol-2-ylthio)methyl]-1H-1,2,3-triazol-1-yl}-N-(p-nitrophenyl)-acetamide (13) 
and 2-(4-{[1-(p-chlorobenzoyl)benzimidazol-2-ylthio)methyl]-1H-1,2,3-triazol-1-yl}-N-(p-
nitrophenyl)acetamide (17) showed significant activity and were subjected to further in-
vestigation at various concentrations in comparison with the reference drug telaprevir 
(TLV). Judging by the results, fifty percent effective concentrations (EC50) of HCV inhibi-
tion for compounds 13 and 17 were 7.8 and 7.6 µmol L–1, respectively, and the 50 % cyto-
toxic concentrations (CC50) were 16.9 and 21.1 µmol L–1, thus resulting in selectivity indices 
of 2–3 (Fig. 3). For telaprevir see also ref. 24. Consulting the inhibitory values for the com-
pounds as anti-HCV agents, we found that the anilide part having an electron withdraw-
ing group, notably nitro group, showed comparatively better activity than other substitu-
ents. The results could be explained according to the Topliss scheme (25, 26), which starts 
with the unsubstituted phenyl. In this work, 2-{4-[(1-acetylbenzimidazol-2-yl-thio)methyl]-
1H-1,2,3-triazol-1-yl}-N-(p-chlorophenyl)-acetamide (5) with p-chlorophenyl showed high-
er affinity than 2-{4-[(1-acetylbenzimidazol-2-yl-thio)methyl]-1H-1,2,3-triazol-1-yl}-N-phen-
ylacetamide (4) with unsubstituted phenyl. For the same reason, 2-{4-[(1 -benzoylbenzimid
azol-2-yl-thio)methyl]-1H-1,2,3-triazol-1-yl}-N-(p-chlorophenyl)acetamide (10) and 
2-(4 -{[1-(p-chlorobenzoyl)benzimidazol-2-yl-thio)methyl]-1H-1,2,3-triazol-1-yl}-N-(p-chlo-
rophenyl)acetamide (15) showed higher activity than 2-{4-[(1-benzoylbenzimidazol-2-yl-
thio)methyl]-1H-1,2,3-triazol-1-yl}-N-phenylacetamide (9) and 2-{4-[(1-(p-chlorobenzoyl)
benzimidazol-2-yl-thio)methyl]-1H-1,2,3-triazol-1-yl}-N-phenyl-acetamide (14), which most 
probably can be attributed to a positive π-effect, a positive α-effect or to a combination of 
both. Since the potency of 2-{4-[(1-benzoylbenzimidazol-2-yl-thio)methyl]-1H-1,2,3-triazol-
1-yl}-N-(p-methylphenyl)-acetamide (12) with p-methylphenyl was lower than that of 
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Fig. 2. Anti-HCV and cytotoxicity of compounds: a) 4, 5, 9, 10, 12–15, and b) compounds 6–8, 11, 16–18 
(SD, n = 3).
2-{4-[(1-(p-chlorobenzoyl)benzimidazol-2-yl-thio)methyl]-1H-1,2,3-triazol-1-yl}-N-phenyl-
acetamide (14), it may be concluded that the positive π-effect is dominant. Accordingly, 
p-nitrophenyl derivatives were synthesized [2-{4-[(1-acetylbenzimidazol-2-yl-thio)methyl]-
1H-1,2,3-triazol-1-yl}-N-(p-nitrophenyl)-acetamide (8), 2-{4-[(1-benzoylbenzimidazol-2-yl-
thio)methyl]-1H-1,2,3-triazol-1-yl}-N-(p-nitrophenyl)-acetamide (13) and 2-(4-{[1-(p-chloro-
benzoyl)benzimidazol-2-yl-thio)methyl]-1H-1,2,3-triazol-1-yl}-N-(p-nitrophenyl)acetamide 
(17). As expected, the latter compounds (13 and 17) showed the highest inhibitory activity 
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CONCLUSIONS
In summary, we have described the synthesis of a series of hybrid molecules, which 
combined two heterocycles (benzimidazole and 1,2,3-triazole) in excellent yields using 
simple, efficient, and fast routes by taking advantage of the click chemistry strategy. These 
benzimidazole/triazoles were tested against HBV and HCV. Among compounds reported 
in this study, compounds 2-{4-[(1-benzoylbenzimidazol-2-yl-thio)methyl]-1H-1,2,3-triazol- 
-1-yl}-N-(p-nitrophenyl)acetamide (13) and 2-(4-{[1-(p-chlorobenzoyl)benzimidazol-2-yl-
thio)methyl]-1H-1,2,3-triazol-1-yl}-N-(p-nitrophenyl)acetamide (17) showed significant ac-
tivity against HCV.
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